Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.

Trial Profile

Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs Grass pollen allergy immunotherapy-BioTech Tools (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions
  • Sponsors BioTech Tools
  • Most Recent Events

    • 05 Jun 2014 New source identified and integrated (ClinicalTrials.gov: NCT02156791)
    • 05 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 30 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top